Compare BOF & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOF | ATRA |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.4M | 38.9M |
| IPO Year | 2023 | 2014 |
| Metric | BOF | ATRA |
|---|---|---|
| Price | $3.39 | $4.69 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 61.7K | ★ 270.3K |
| Earning Date | 05-14-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.36 | ★ 122.52 |
| EPS | N/A | ★ 2.57 |
| Revenue | $3,184,018.00 | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $1.83 |
| Revenue Growth | ★ 258.20 | N/A |
| 52 Week Low | $1.53 | $3.92 |
| 52 Week High | $4.95 | $19.15 |
| Indicator | BOF | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 40.10 |
| Support Level | $2.79 | $4.06 |
| Resistance Level | $3.47 | $5.80 |
| Average True Range (ATR) | 0.26 | 0.58 |
| MACD | -0.06 | -0.06 |
| Stochastic Oscillator | 3.16 | 0.00 |
Branchout Food inc is engaged in the development, marketing, sale, and distribution of plant-based, dehydrated fruit and vegetable snacks and powders. Its products are currently manufactured for the company by contract manufacturers based in South America and North America that produce dehydrated fruit and vegetable products for the company using a new proprietary dehydration technology that it licenses from a third party. The Company's customers are located throughout the United States. Its current primary products are BranchOut Snacks, BranchOut Powders, and BranchOut Industrial Ingredients.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).